When the PD-1 inhibitor Nivolumab is combined with the CTLA-4 inhibitor Ipilimumab, it significantly increases the progression-free survival rate and median overall survival in advanced NSCLC patients, greatly improving the patient prognosis with more durable therapeutic effects [369]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.